Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Curr+Opin+Oncol 2017 ; 29 (4): 268-74 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Adult desmoid tumors: biology, management and ongoing trials #MMPMID28489620
Penel N; Chibon F; Salas S
Curr Opin Oncol 2017[Jul]; 29 (4): 268-74 PMID28489620show ga
Purpose of review: To summarize the current knowledge about the biology and clinical management of adult desmoid tumors. Recent findings: In the past decade, we have learned that desmoid tumors are driven by alterations of the Wnt/APC/?-catenin pathway, sporadic desmoid tumors are associated with somatic mutations of CTNNB1, and germline mutations of APC and somatic mutations of CTNNB1 are probably mutually exclusive. One-third of desmoid tumors are misdiagnosed; a second pathological opinion is therefore of major importance for desmoid tumor. Surgery is no longer regarded as the cornerstone of desmoid tumors; several retrospective studies have demonstrated the safety of a ?wait and see? policy in sporadic abdominal wall desmoid tumor. Desmoid tumors is no longer regarded as an absolute contraindication for pregnancy. At least two new investigational drugs targeting the Wnt/APC/?-catenin pathway are currently being developed. Summary: The management of desmoid tumors requires multidisciplinary expertise by an experienced team. We must fully understand the physiopathology of the disease (factors influencing the natural history of the disease) and learn how to avoid desmoid tumors occurrence in patients with APC germline mutations, identify reliable prognostic/predictive factors and better assess the efficacy of systemic treatment.
free
free
free
Curr+Opin+Oncol 2017 ; 29 (4): 268-74
